Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
Collegium Pharmaceutical, Inc. (COLL) filed a Form 144 reporting a proposed sale of 4,861 common shares. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ with an aggregate market value of $184,880.87. The company reports 31,502,127 shares outstanding, giving context to the size of this proposed sale relative to the total share base.
The filing shows the shares were acquired via an option granted on 02/05/2020 from the issuer and the transaction lists cash as the form of payment. The filer reports no securities sold in the past three months and makes the required representation that they are not aware of material nonpublic information about the issuer.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 1,521,170 shares of Collegium Pharmaceutical common stock, representing 4.82% of the class. The filers state they have sole voting and sole dispositive power over these shares and no shared voting or dispositive power. The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also notes that certain funds managed by Renaissance have rights to receive dividends and sale proceeds related to these shares. The report identifies one filer as an investment adviser and the other as a holding company.
John G. Freund, a director of Collegium Pharmaceutical, reported sales of common stock with an execution date of 08/08/2025. The filing records a direct sale of 11,659 shares at a weighted-average price of $34.3632, with individual sale prices ranging from $34.27 to $34.535. The Form 4 also includes items showing 70,658 shares marked as disposed and an indirect position of 8,625 shares held through Skyline Venture Management V, LLC. Following the reported transactions the filing identifies 23,129 shares held indirectly by the John Freund Family Partnership IV, L.P. The reporting person disclaims beneficial ownership of shares held by those entities except to the extent of his proportionate pecuniary interest.
The Schedule 13G/A filed for Collegium Pharmaceutical shows Principal Global Investors beneficially owns 1,466,506 shares of Collegium common stock, representing 4.6% of the class. The filing reports shared voting power and shared dispositive power for all 1,466,506 shares and no sole voting or dispositive power. The issuer is identified as Collegium Pharmaceutical (common stock, $0.001 par). The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.